| Product Name | Human Asc-type amino acid transporter 1 (SLC7A10) ELISA Kit |
|---|---|
| Description | SLC7A10, in association with 4F2HC (SLC3A2), mediates high-affinity transport of D-serine and several other neutral amino acids.The deduced 530-amino acid protein contains 12 transmembrane regions and a conserved cysteine residue (cys160) in the putative extracellular loop between transmembrane domains 3 and 4. This residue was presumed to be linked to 4f2hc via a disulfide bond. Northern blot analysis detected a 1.9-kb transcript in mouse brain and lung, with weaker expression in placenta. A single 4.4-kb transcript was expressed in small intestine.ASC1 shares 91% identity with mouse Asc1. Northern blot analysis detected 1.3-, 2.0-, 4.3-, and 6.0-kb transcripts in brain, heart, placenta, skeletal muscle, and kidney. The 2.0-kb transcript predominated in brain. This assay has high sensitivity and excellent specificity for detection of Human SLC7A10. No significant cross-reactivity or interference between Human SLC7A10 and analogues was observed. |
| Synonyms | FLJ20839, HASC-1, asc-1, asc-type amino acid transporter 1|solute carrier family 7, (cationic amino acid transporter, y+ system) member 10|solute carrier family 7, member 10 |
| Method | Sandwich ELISA |
| Detection Range | 0.156-10 ng/mL |
| Sensitivity | 0.055 ng/mL |
| Reactivity | Human |
| Sample Types | Serum, Plasma, Other biological fluids. |
| Background | SLC7A10, in association with 4F2HC (SLC3A2), mediates high-affinity transport of D-serine and several other neutral amino acids.The deduced 530-amino acid protein contains 12 transmembrane regions and a conserved cysteine residue (cys160) in the putative extracellular loop between transmembrane domains 3 and 4. This residue was presumed to be linked to 4f2hc via a disulfide bond. Northern blot analysis detected a 1.9-kb transcript in mouse brain and lung, with weaker expression in placenta. A single 4.4-kb transcript was expressed in small intestine.ASC1 shares 91% identity with mouse Asc1. Northern blot analysis detected 1.3-, 2.0-, 4.3-, and 6.0-kb transcripts in brain, heart, placenta, skeletal muscle, and kidney. The 2.0-kb transcript predominated in brain. |
| Supplier | Abebio |
All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.
